Rigel Pharmaceuticals
RIGL
123 hedge funds and large institutions have $250M invested in Rigel Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 21 closing their positions.
85% more call options, than puts
Call options by funds: $643K | Put options by funds: $348K
23% more capital invested
Capital invested by funds: $203M → $250M (+$47.2M)
18% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 38
9.29% more ownership
Funds ownership: 68.59% → 77.88% (+9.3%)
5% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 21
1% more funds holding
Funds holding: 122 → 123 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLGM
Capitolis Liquid Global Markets
New York
|
+$14.1M |
| 2 |
AC
Armistice Capital
New York
|
+$7.39M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.2M |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$4.3M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.83M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$2.54M |
| 2 |
Goldman Sachs
New York
|
-$2.18M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$2.18M |
| 4 |
Renaissance Technologies
New York
|
-$2M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$1.44M |
RIGL Hedge Fund Activity: Q1 2025 in Review
123 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q1 2025, worth a combined $250M — up 23% from $203M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RIGL positions and 21 closed out — a net gain of 1 holder — while 45 added to existing stakes and 38 trimmed.
The largest buyer was Capitolis Liquid Global Markets, opening a new position worth an estimated $14.1M. The largest seller was JP Morgan Chase, cutting an estimated $2.54M.
- 123 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q1 2025, up from 122 in Q4 2024.
- Funds reported $250M of Rigel Pharmaceuticals stock for Q1 2025, up 23% quarter-over-quarter.
- 22 funds opened new Rigel Pharmaceuticals positions in Q1 2025 and 21 closed out, a net change of +1 holder.
- The largest Rigel Pharmaceuticals buyer in Q1 2025 was Capitolis Liquid Global Markets, an estimated $14.1M added.
- The largest Rigel Pharmaceuticals seller in Q1 2025 was JP Morgan Chase, an estimated $2.54M sold.
Based on aggregated 13F filings for Q1 2025.